Hedge Fund - Cormorant Asset Management

The biotech industry is regaining ground it lost in 2016 at full speed. The sector was very hot until around mid-2015, with the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) gaining over 370% between...

*  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...

*  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...

Bihua Chen's Cormorant Asset Management is one of some 750 investors that we track and whose quarterly 13F filings we analyze to identify stocks that they are collectively bullish on. Separately, we calculated...

Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) has a new shareholder in the form of Bihua Chen's Cormorant Asset Management. As per a new 13G filing with the Securities and Exchange Commission, the fund...

A recent 13G filing with the Securities and Exchange Commission revealed that Bihua Chen's Cormorant Asset Management has boosted its stake in Myokardia Inc (NASDAQ:MYOK) to 1.61 million shares, which...

In a new 13G filing with the SEC, Bihua Chen's Cormorant Asset Management reported owning 2.35 million shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), which account for 5.37% of the company...

According to a new 13G filing with the Securities and Exchange Commission, Bihua Chen's Cormorant Asset Management owns 900,000 shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP), which amass 9.7% of...

Bihua Chen's Cormorant Asset Management has revealed a position in Clearside Biomedical Inc (NASDAQ:CLSD), through a 13G filing issued with the SEC yesterday. The filing, which has a June 1 Date of...